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a  b  s  t  r  a  c  t
Background:  The  first  case  of  COVID-19  infection  in  Saudi  Arabia  was  reported  in Qatif  on  March  2nd,
2020.  Here,  we  describe  the  clinical  characteristics  of  the initial  COVID-19  patients  in  that  area.
Methods:  This  is  an  observational  study  describing  the  clinical  presentation,  radiographic  and  laboratory
data  of  COVID-19  cases.
Results:  From  March  1st,  2020 to April  5th,  2020  we  identified  a total  of  82 adult  COVID-19  patients.  The
median  age  of the  patients  was  50  years,  with  a range  of 30  to 60 years  and  most  of  patients  were  female
54 (65.9%).  Of  all the  patients,  29  (35.4%)  were  contacts  and  43  (52.4%)  were  returning  travelers,  mainly
from  Iraq  (65%  of  the  total returning  travelers).  Comorbidities  were  present  in 50%  of  patients,  G6PD
deficiency  in  33%,  hypertension  in  27%, and  diabetes  mellitus  in  26%.  Chest  radiographs  were  abnormal
in  46%  of symptomatic  and  15.5%  of  asymptomatic  patients  (P value  = 0.0035).  Of all  patients,  4 (4.87%)
required  intensive  care  admission.  There  was no  significant  difference  in  time  to  negative  RT-PCR  with
mean  days  to negativity  of  13.6  and  16.9 for asymptomatic  and  symptomatic  group,  respectively  (P  value
=  0.42).
Conclusions:  In  the  initial  Epicenter  of the  COVID-19  in  Saudi  Arabia,  the majority  of  the  patients  were
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Health  Sciences.  This  is  an
Introduction
The emergence in late December 2019 of the severe acute respi-
ratory syndrome coronavirus 2 (SARS-CoV-2) had caused a global
pandemic. The SARS-CoV-2 is genetically similar to SARS-CoV [1].
The initial cluster of cases were identified in Wuhan city, China
and were related to a seafood market and later SARS-CoV-2 infec-
tions were secondary to community transmission from one person
to another [1,2]. Subsequently, studies demonstrated human-to-
human transmission of SARS-CoV-2 through either droplets or
direct contact [3]. Initial cases occurred mainly among travelers
from China and those who have had contact with such travelers.
∗ Corresponding author at: P.O. Box 76; Room A-428-2, Building 61, Dhahran
Health Center, Saudi Aramco, Dhahran 31311, Saudi Arabia.
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owever, ongoing local transmission has driven the initial out-
reaks in all countries around the globe including countries in
sia, Europe, North America and the Middle East [4,5]. The ini-
ial reported cases of COVID -19 in the Arabian Gulf region were
elated to travelers who  came from Iran and Iraq to Bahrain and
uwait [6,7]. The first case of the COVID-19 infection reported in
audi Arabia was  in Qatif, Eastern province in a person who came
rom Iran [6]. The Kingdom of Saudi Arabia had taken extensive
reemptive strategies to curtail the spread of SARS-CoV-2 trans-
ission [8,9]. There are limited published studies about COVID-19
n patients from the Gulf Cooperation Council (GCC) [10–12], and
hus here we present the clinical presentation of the initial cases
hat were diagnosed in Saudi Arabia.dulaziz University for Health Sciences. This is an open access article under the CC
J.M. AlJishi et al. Journal of Infection and Public Health 14 (2021) 6–11
Table  1
Characteristics and underlying comorbidities of included COVID-19 patients.
Characteristics All patients (N = 82) Symptomatic patients (N = 37) Asymptomatic patients (N = 45) P value
Median age (IQR) – yr. 50 (24) 44 (25) 53 (25) 0.907
Male  – no. (%). 28 (34.1) 13 (35.1) 15 (33.3) 0.524
Female – no. (%). 54 (65.9) 24 (64.9) 30 (66.7) 0.524
Asthma – no. (%). 4 (4.9) 1 (2.7) 3 (6.7) 0.623
Diabetes Mellitus – no. (%). 22 (26.8) 5 (13.5) 17 (37.8) 0.023
Hypertension no. (%). 22 (26.8) 10 (27.0) 12 (26.7) 1.000
Cerebrovascular disease no. (%). 2 (2.5) 0 (0) 2 (4.4) 0.248
Malignancy – no. (%). 3 (3.7) 1 (2.7) 2 (4.4) 1.000
Sickle  cell trait – no. (%). 6 (7.3) 3 (8.1) 3 (6.7) 0.592
4) 15 (33.3) 0.366
2) 13 (28.9) 0.133































G6PD  – no. (%). 27 (32.9) 12 (32.
Contact – no. (%). 29 (35.4) 16 (43.
Travel  – no. (%). 43 (52.4) 11 (29.
Methods
This is an observational descriptive study of adult patients
(more than 14 years of age) with confirmed SARS-CoV-2 infec-
tion from March 1st, 2020 until April 5th, 2020 at Qatif Central
Hospital. All patients who were diagnosed at that time were
required by the Saudi Ministry of Health to be hospitalized
including those who were asymptomatic [7]. The diagnosis of SARS-
CoV-2 SARS-CoV-2 infection was based on a positive real-time
reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay
of SARS-CoV-2 based on nasal and pharyngeal swab specimens as
described previously [13].
We  used a pre-determined data extraction excel sheet to gather
the different variables. The sociodemographic, epidemiological,
clinical signs and symptoms, comorbidities, laboratory and radi-
ological results were extracted from available medical records. We
included time to clinical improvement (time from admission to dis-
charge), need for intensive care unit (ICU) admission and invasive
ventilation, presence of multiorgan failure, or mortality. The onset
of the disease was defined as the day when symptoms appeared.
Thrombocytopenia was defined as a platelet count of less than
150,000 cells per cubic millimeter according to American society of
hematology. Lymphocytopenia was considered when lymphocyte
count was ≤1500 per cubic millimeter [10,14]. Fever was defined as
an axillary temperature of 37.5 ◦C or higher, and ARDS was  defined
according to the Berlin definition [15]. The study was  approved by
the institutional research ethic committee of Qatif central hospital
(QCH), Eastern province, Saudi Arabia (QCH-SREC0195/2020).
Statistical analysis
Descriptive analysis of demographics, patients clinical and
laboratory characteristics were expressed as frequencies and per-
centages for categorical data and mean and standard deviation (SD)
or median and interquartile range (IQR) for continuous data. Com-
parison of asymptomatic and mildly symptomatic disease was done
using chi square (2) test or Fisher exact test as appropriate for
categorical outcomes. Student t-test was used for continuous vari-
ables. Univariate and multivariate logistic regression methods were
used to adjust for the effect of age, gender, comorbid illness, and
outcome. All analyses were performed using IBM Statistics SPSS
version 21. P value of ≤0.05 was considered significant.
Results
During the study period between March 1, 2020 and April
5,2020, there was a total of 82 confirmed COVID-19 patients. The
median age of the patients was 50 (IQR 25), with a range from 30
to 60 years and most patients were female 54 (65.9%) (Table 1). Of
all cases, 29 (35.4%) were contacts and 43 (52.4%) were returning





ig. 1. Percentage of Common Symptoms among Symptomatic COVID-19 patients.
OB: Shortness of breath.
omorbidities were present in nearly half of patients, with G6PD
eficiency being the highest (33%), hypertension (27%), and dia-
etes mellitus (26%). Of the total cases, sickle cell trait was seen
n 6 (7.3%) and G6PD deficiency was  seen in 27 (32.9%) with no
ifference between asymptomatic and symptomatic patients.
There were 45 (55%) asymptomatic patients and the remaining
ere symptomatic patients (Table 1). Asymptomatic patients were
ore likely to have diabetes mellitus (37.8% vs. 13.5% (P = 0.023)
nd being travelers (71.1% vs. 29.7%; P = <0.0001). Of the patients
ith symptoms, the most frequent symptoms were cough (75%),
ever (44.4%), and sore throat (44.4%) (Fig. 1).
Chest radiographs were abnormal in 46% of the symptomatic
nd 15.5% of asymptomatic patients (P value = 0.0035) (Fig. 2).
nilateral pulmonary infiltration was  observed in 8 (21.6%) of
ymptomatic and 5 (11%) of asymptomatic patients (P value =
.2337), whereas bilateral infiltrates were seen in 9 (24.3%) and
 (4.4%) of symptomatic and asymptomatic patients, respectively
P = 0.0191).
Laboratory findings of the included patients are shown in
able 2. The majority of the patients had normal WBC, neutrophil
ounts, and lymphocyte counts. However, there was  statistically
ignificant difference in the mean of CRP of 2.19 and 0.44 in symp-
omatic and asymptomatic patients, respectively (P = 0.004). In
ddition, LDH was  higher in symptomatic (215.57) than asymp-
omatic (182.79) patients (P = 0.016). The Neutrophils/Lymphocyte
ount Ratio (NLR) was  1.77 and 1.30 for the symptomatic and
symptomatic cases, respectively (P = 0.091). There was  no sig-
ificant difference in the time to negative RT-PCR in both groups
s shown in Fig. 3 with mean days to negative of 13.6 and 16.9
or asymptomatic and symptomatic group, respectively (P value =
.42).
Of all the patients, 23% received antimicrobial therapy, 29.3%
ad antiviral therapy and 25.6% had hydroxychloroquine. Of all the
atients, 4 (4.87%) required intensive care admission as shown in
able 3.
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Table  2
Common Laboratory Findings among COVID-19 Patients as a group and in symptomatic and asymptomatic groups.
Parameter – mean All patients (N = 82) Symptomatic patients (N = 37) Asymptomatic patients (N = 45) P value
WBC  x109 cells/L 5.19 4.86 5.46 0.564
Neutrophils x109 cells/L 2.91 3.77 2.21 0.179
Lymphocytes x109 cells/L 2.39 3.02 1.87 0.275
NLR* 1.51 1.77 1.30 0.091
Platelets x109 cells/L 256.0 247.19 263.24 0.424
ESR  mm/hr 26.07 29.06 23.31 0.337
CRP  mg/L 1.27 2.19 0.44 0.004
LDH  mg/dl 197.95 215.57 182.79 0.016
D-Dimer 0.73 0.78 0.69 0.668
Ferritin ng/mL 339.11 398.98 288.22 0.199
ALT  U/L 23.78 27.22 20.94 0.179
AST  U/L 21.45 25.69 18.15 0.260
Total  Bilirubin mg/dl 8.75 10.52 7.22 0.082
Conjugated Bilirubin mg/dl 4.31 5.16 3.61 0.195
Protein g/dl 74.08 74.21 73.98 0.897
Albumin mg/dl 43.21 42.04 44.14 0.128
ALP  IU/L 73.31 72.11 74.29 0.783
Urea  mmol/L 5.05 4.85 5.21 0.794
Creatinine umol/L 79.27 97.95 63.92 0.193
PT  16.77 19.58 14.45 0.381
PTT  29.52 30.20 28.95 0.305
INR  1.14 1.35 0.96 0.243
CK  U/L 101.19 134.22 72.88 0.053
CKMB  U/L 22.04 18.561 25.01 0.287
* NLR is Neutrophils/Lymphocyte Count Ratio.
Table 3
Characteristics of Critical COVID-19 patients.
Total patients (n = 4) Time till transfer* SOFA score Mortality estimation NLR
Patient no.1 1 14 ≥95.2% 4.170
Patient no.2 1 2 ≤33.3% 1.848



























Patient no.4 3 
* Time in days from the first day of hospital admission to ICU admission; SOFA, Se
Discussion
In this study, we present the clinical, laboratory data and radio-
graphic features of the initial COVID-19 patients that were reported
from Saudi Arabia. The majority of these patients were travel-
related and were asymptomatic and based on the ministry of health
regulation at that time all patients were required to be hospi-
talized. The Kingdom of Saudi Arabia had taken strict measures
to control the COVID-19 pandemic [6,7]. The country had desig-
nated COVID-19 hospitals to provide management for COVID-19
patients. Healthcare workers are advised to use droplet and con-
tact precautions when dealing with suspected COVID-19 patients.
These precautions are upgraded to airborne infection transmission
when performing aerosol generating procedures. In addition, the
Kingdom had adopted early utilization of universal masking even
in public areas coupled with social distancing and hand hygiene.
These precautionary measures are fundamental in the prevention
of COVID-19 [16].
The mean age of the patients in the current study was  50 years
and was slightly higher than the reported mean age in previ-
ous studies from Saudi Arabia that reported 36 years [10] and a
median age of 44 years in another study [12]. The clinical picture
of COVID-19 cases is variable and ranges from asymptomatic, to
symptomatic, and severe disease [17,18]. Only a small number (4
patients; 4.8%) in our sample required ICU admission which was
different from other studies reporting ICU admission in 50% of the
patients [8] but is similar to the rate of 4.7% reported in a study
from Saudi Arabia [10] and another study from China [14]. This dif-
ference is easily explained by the fact that we had to admit even






tial Organ Failure Assessment; NLR, Neutrophil-Lymphocyte Ratio.
owever, the number of the critical cases in this study is small to
ake any generalizable conclusions.
The clinical presentations of symptomatic patients showed that
ever was present in less than half of the patients. The presence of
ever other studies is variable and ranges from 36% to 98.6% [11,17].
n a large study of 24,410 adults infected by SARS-CoV-2, 78% had
ever on presentation [19].
About half of the included patients had comorbidities and this
s in contrast to the cited percentage of 32%–93% in different stud-
es [17,20]. There are various pre-existing comorbidities that were
ssociated with COVID-19. We  found hypertension (27%) and dia-
etes mellitus (26%). In a systematic review that included patients
ill April 7th, 2020, 11% of the included patients had diabetes melli-
us [21]. Other studies had also showed high rates of hypertension
nd diabetes mellitus among COVID-19 patients including studies
rom Saudi Arabia [10,11], Oman [22] and other parts of the world
2,23,24].
In this study, 54% of the cases were asymptomatic. Asymp-
omatic COVID-19 is one of the features of this pandemic. The exact
ercentage of asymptomatic disease is not known [18,25]. The large
ercentage of asymptomatic patients in this study is likely related
o the inclusion of returning travelers. Asymptomatic COVID-19
revalence is related to the tested groups, and was about 50% in
he ship cruise and nursing facilities [26–30]. In a large study of
bout 500 COVID-19 patients, asymptomatic patients represented
.9% of the cases [31]. And another study from Saudi Arabia showed
hat 9.3% were asymptomatic [10].In the current study, there was  no difference in the WBC
etween symptomatic and asymptomatic patients. In a previous
tudy, the mean WBC  was 5.00 (4.03–6.28) in symptomatic and
.11 (4.15–6.41) in asymptomatic patients [31]. This difference
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Fig. 2. A portable anterior-posterior chest radiograph showing bilateral infiltrate in
an  asymptomatic (A) and symptomatic (B) COVID-19 patients.
Fig. 3. Survival Plot for days to negative comparing asymptomatic (solid line) and
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as  small but was statistically significant. Most of the cases in
he current study did not have lymphopenia. However, previous
tudies showed lymphopenia in 70% of patients [17]. The Neu-
rophils/Lymphocyte Count Ratio (NLR) of ≥3.13 was  used as a
redictor of the need for intensive care unit admission. It was  found
hat elevated NLR and age were significantly associated with illness
everity [32]. Thus, it is not surprising that the NLR was not statisti-
ally significant in the symptomatic and asymptomatic cases in the
urrent study. However, patients who  required ICU admissions had
igher NLR which was proportionally related to the calculated mor-
ality rate. In addition, the case fatality rate had varied and likely
elated to the presence of comorbidities [8,17]. In a recent study,
here was  a disparity in the death rates where 22.4% of COVID-19
eaths in the USA were among African Americans who  constitute
3.4% of the USA population [33]. This is an interesting observation
nd deserves further evaluation in this part of the world.
CRP is an inflammatory marker and had been used in the early
iagnosis of pneumonia. We  found that symptomatic patients had
igher level of CRP than asymptomatic patients. In a study of 15
symptomatic patients, 10 (66.7%) had elevated CRP levels [34].
here was  a correlation between the level of CRP and severity
f COVID-19 cases. In one study, CRP levels increased as the dis-
ase progressed and the mean (±SD) was 1.52 ± 1.56 in mild
isease compared to 16.76 ± 18.38 in moderate group, 54.15 ±
.06 in severe disease and 105.00 ± 12.73 in critical group [35].
he progression of COVID-19 was  associated with increasing CRP
n another study and was a poor prognostic factor [36]. In addition,
RP elevation and eosinopenia had been used as triage markers in
ever clinics [37].
There was  no difference in the levels of ferritin and D-dimer
etween asymptomatic and mildly symptomatic patients in the
urrent study. Ferritin is an acute phase reactant and it had been
eported to increase as the disease severity increases and thus had
een used as a prognostic factors [36]. In one study, ferritin levels
ere elevated in patients with severe disease COVID-19 or worse
isease [38]. Similarly, D-dimer levels statistically significantly
igher in severe disease compared to mild and moderate disease
38,39]. Thus, these studies explain the reason that there was  no
ifference in the current study that did not include severe disease.
n addition, there are different studies documenting no significant
ifference in cytokines between asymptomatic and symptomatic
atients [40] and other studies documenting such a difference.
hese differences in the various studies including our study may
e related to the population of patients being included, the time
f the observations during the spectrum and course of COVID-19
isease.
In Qatif area, Glucose-6-phosphate dehydrogenase deficiency
G6PD) deficiency and sickle cell disease are common hemato-
ogic problems with rates of 30.6% and 20–30% of newborns are
eterozygous for the sickle gene, respectively [41,42]. The cur-
ent study showed that sickle cell disease was present in 6 (7.3%)
nd G6PD deficiency in 27 (32.9%) of patients with no difference
etween asymptomatic and symptomatic patients. There was  no
revious study describing the association between G6PD deficiency
nd COVID-19 [43]. However, it was  shown that G6PD deficiency
nhances human coronavirus 229E experimental infection [41]. It
as  assumed that G6PD deficiency may  result in increased hemol-
sis and thus death in patients with COVID-19 [44]. We also found
o difference in the occurrence of sickle cell trait between asymp-
omatic and systematic patients and only one patient had sickle cell
isease. In a recent study from Bahrain, 6 of 378 SCD patients who
ere tested for SARS-CoV-2 were positive [45]. The extent of theffect of hematologic disorders on patients with COVI-19 is not yet
stablished [46–48].
In the current study, chest radiographs were abnormal in 46%
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routine chest radiography is not usually done in asymptomatic
patients. One study in China showed that 94% of 58 asymptomatic
patients had CT-scan findings [8]. Another study showed that 60%
of asymptomatic patients had abnormalities confined to one lung
and 90% of mildly symptomatic patients had abnormalities in both
lungs [9]. Similarly, we found that bilateral radiographic abnormal-
ities were more common in symptomatic patients.
One of the interesting observations in this study is the fact that
there was no significant difference in the time to negative RT-PCR in
asymptomatic and symptomatic groups. The sensitivity of RT-PCR
is usually low in early stages of SARS-CoV-2 infection and ranges
between 45 and 60% [49]. SARS-CoV-2 had a modest viral loads in
the early stage and peaked approximately 10 days after symptoms
onset [50]. Reasons for low sensitivity of PCR may  include variations
in the accuracies of different tests, low initial viral load or improper
clinical sampling [49]. Understanding the viral dynamics profile of
SARS-CoV-2 is an important tools to enhance the knowledge of the
disease and mode of transmission [51]. In this study, the mean days
to negative RT-PCR was 13.6 for asymptomatic and 16.9 for symp-
tomatic patients. Previous studies showed that the median duration
of viral shedding was 19 days (range, 6–37 days) from initial viral
detection in 23 patients with mild or no symptoms [52]. Another
study showed that more than one month lapsed prior to achieving
PCR negativity in asymptomatic patients [53]. It is also important to
acknowledge the phenomena of intermittent positivity as detected
by RT-PCR as reported in previous studies [13,54,55].
In this study, we described differences and similarities between
asymptomatic and symptomatic COVID-19 patients. The study is a
retrospective and mainly a descriptive study and as such has few
limitations. The study did not include sufficient number of severe
cases requiring intensive care management, and did not span over a
long follow up time to characterize the outcome of all cases. Being a
cross-sectional study also limited full description and characteriza-
tion of the clinical courses and outcomes. In addition, this is a single
center study and included mainly returning travelers who had to be
hospitalized to comply with the local guidelines. The study also did
not address the predictors of progression to symptomatic disease
vs. those factors contributing to patients remaining to be asymp-
tomatic. The study included all hospitalized patients but a large
percentage of them would not require hospitalization when consid-
ered at this time of the pandemic when such patients are cared for
at home. Thus, the study results are not generable to all hospitalized
patients.
In conclusion, initially reported COVID-19 cases in Saudi Ara-
bia were mainly asymptomatic returning travelers. There was  a
significant difference in radiographic presentation between asymp-
tomatic and symptomatic patients and the majority of patients
had comorbidities. The study compared asymptomatic and symp-
tomatic patients and further studies are needed to further elucidate
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